ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

LOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ARS (SPRY) To Contact Him Directly To Discuss Their Options

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026 inclusive (the “Class Period”). ARS Pharmaceuticals is a clinical stage biopharmaceutical company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options

Robbins LLP informs shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, including anaphylaxis.

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company

Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy® received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors who lost money on SPRY are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of the securities laws.

No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights.

neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions

Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle-free epinephrine without age restrictions

neffy delivers $72.2 million of U.S. net product revenue in first full year